ZGGS15

News alerts, weekly reports and conference planners

Company:

Suzhou Zelgen

Drug class:

LAG-3 inhibitor, TIGIT inhibitor

Related drugs:

‹

›

A novel anti-LAG-3/TIGIT bispecific antibody exhibits potent anti-tumor efficacy in mouse models as monotherapy or in combination with PD-1 antibody. (PubMed, Sci Rep)

The tumor volume inhibition rate for ZGGS15 at 2 mg/kg was 69.70%, and for ZGGS15 at 5 mg/kg plus nivolumab at 1 mg/kg, it was 94.03% (p < 0.001). Our data reveal that ZGGS15 exhibits potent anti-tumor efficacy without eliciting ADCC or CDC or causing cytokine production, therefore having a safe profile.

1 day ago

Preclinical • Journal • Combination therapy

TIGIT (T Cell Immunoreceptor With Ig And ITIM Domains 2) • PVR (PVR Cell Adhesion Molecule)

Opdivo (nivolumab) • ZGGS15

5ms

ZGGS15, a Novel IgG4 Bispecific Monoclonal Antibody Targeting Both LAG-3 and Tigit, Demonstrates Outstanding Anti-Tumor Activity and Can be Used As Monotherapy or in Combination with Anti-PD-1 Antibodies for Cancer Immunotherapy (ASH 2023)

When combined with nivolumab, ZGGS15 can further enhance the T cell activation in a dose-dependent manner. Additionally, ZGGS15 does not elicit ADCC or CDC, therefore avoiding the cross-reaction of non-target binding. Finally, ZGGS15 does not induce cytokine production, mitigating any potential adverse effects of CRS.

5 months ago

Combination therapy

CD8 (cluster of differentiation 8) • IFNG (Interferon, gamma) • IL6 (Interleukin 6) • LAG3 (Lymphocyte Activating 3) • TNFA (Tumor Necrosis Factor-Alpha) • TIGIT (T Cell Immunoreceptor With Ig And ITIM Domains 2) • CD4 (CD4 Molecule) • IL2 (Interleukin 2) • IL10 (Interleukin 10) • PVR (PVR Cell Adhesion Molecule)

LAG3 expression

Opdivo (nivolumab) • ZGGS15

12ms

Study of ZGGS15 in Patients With Advanced Solid Tumors (clinicaltrials.gov)

P1, N=36, Not yet recruiting, Suzhou Zelgen Biopharmaceuticals Co.,Ltd

12 months ago

New P1 trial • Metastases

ZGGS15